Bisphosphonates and atypical femoral fractures.
Pozzi
Samantha
S
Raje
Noopur
N
D019386:Alendronate / Q000008:administration & dosage; D050071:Bone Density Conservation Agents / Q000009:adverse effects*; D001862:Bone Resorption / Q000517:prevention & control; D004164:Diphosphonates / Q000008:administration & dosage / Q000009:adverse effects*; D005264:Femoral Fractures / Q000139:chemically induced; D006620:Hip Fractures / Q000139:chemically induced*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage; D010020:Osteonecrosis / Q000139:chemically induced; D012307:Risk Factors; D000077211:Zoledronic Acid
D050071:Bone Density Conservation Agents; D004164:Diphosphonates; D007093:Imidazoles; D000077211:Zoledronic Acid; D019386:Alendronate